Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


RSV OR THE FLU? NOW YOU KNOW IT IMMEDIATELY

Janssen Diagnostics has developed a molecular diagnostic test which will be used with the Biocartis’ Idylla™ platform, to determine Influenza and …


Ebola diagnostics – faster, safer, and more accurate

“Last year the Ebola outbreak kick-started the development of a fast and accurate Ebola test to be used with Biocartis’ Idylla™ platform” - says D…

POPULAR TAGS

Urine HPV screening

Written by JVdB on in the category news with the tags , , .


HPV is the most common sexually transmitted infection (1). While most infections are subclinical, two virus serotypes are known to be carcinogenic. The lack of symptoms and the discomfort associated with traditional screening methods, such as pap tests or swabs, lead to an ineffective disease prevention as 40% of women in the EU do not participate in local government lead screening programs. However, the University of Antwerp spin-off Novosanis has developed a non-invasive alternative that can overcome this barrier.

Their home self-sampling device, Colli-PeeTM, allows an easy collection of first-void urine of both men and women. Thanks to its innovative design, the disposable product collects the first 20 mL and lets the rest flow through freely. The collected fraction contains the highest concentration of DNA, RNA and protein for analysis. However, it is usually not collected properly in traditional urine samples as women find it difficult to aim and men to interrupt their stream.

The design and development of Colli-PeeTM was funded by the IWT and was awarded the 2015 IWT award for the project with the highest social relevance. Indeed, HPV diagnosis is important as the WHO has estimated there were 528.000 cases of cervical cancer in 2012 worldwide, resulting in 266.000 deaths (2). Furthermore, first-void urine can not only be used for the detection of HPV, but also for other STI’s such as chlamydia or gonnorhea, or even prostate cancer biomarkers.

In early 2015, the device obtained CE marking and was ready for large scale production. Novosanis acquired EU funding to validate the assays and support to perform a feasibility study.  The suitability of HPV DNA detection in first-void urine might replace the current screening methods.

References

(1) Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Banez Ocefemia MC, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93.

(2) World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.12. ISBN 9283204298.

Read more about: , , .

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


RSV OR THE FLU? NOW YOU KNOW IT IMMEDIATELY

Janssen Diagnostics has developed a molecular diagnostic test which will be used with the Biocartis’ Idylla™ platform, to determine Influenza and …


Ebola diagnostics – faster, safer, and more accurate

“Last year the Ebola outbreak kick-started the development of a fast and accurate Ebola test to be used with Biocartis’ Idylla™ platform” - says D…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin KU Leuven UGent Janssen Turnstone XpandInnovation Flanders.bio V-Bio Ventures Itera Life Science GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.